EX-10.18



 Exhibit 10.18 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 EXCLUSIVE LICENSE AGREEMENT 

This Agreement is made and entered into as of the 30th day of September, 2013 (“Effective Date”), by and between the University of
Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 200 Gardner Steel Conference Center, Thackeray and O’Hara
Streets, Pittsburgh, Pennsylvania 15260 (“University”), and EXAGEN DIAGNOSTICS, INC., a corporation organized and existing under the laws of Delaware, having an office at 800 Bradbury Drive SE Suite 108, Albuquerque, NM 87106
(“Licensee”). 
 WHEREAS, UNIVERSITY is the owner by assignment from the inventors of certain PATENT RIGHTS, entitled
“Diagnosis and Monitoring of Systemic Lupus Erythematosus,” developed by Drs. Susan Manzi and Joseph Ahearn of the UNIVERSITY faculty, consisting of certain patents and patent applications, and the UNIVERSITY has the right to grant
licenses under such PATENT RIGHTS; 
 WHEREAS, the parties have previously entered into a United States-restricted Amended and Restated
License Agreement with respect to the PATENT RIGHTS, effective August 2, 2011 and amended on May 17, 2012, and whereas the parties are contemporaneously entering into a Second Amendment To the Amended and Restated License Agreement with
respect to the PATENT RIGHTS; 
 WHEREAS, University desires to have the PATENT RIGHTS utilized worldwide in the public interest; 

WHEREAS, LICENSEE has represented to UNIVERSITY, to induce UNIVERSITY to enter into this Agreement, that LICENSEE is experienced in the
development, production, manufacture, marketing and sale of products and/or the use of similar products to the LICENSED TECHNOLOGY and that LICENSEE shall commit itself to a thorough, vigorous and diligent program of exploiting the PATENT RIGHTS so
that public utilization results therefrom; and 







 WHEREAS, Licensee desires to obtain a license under the non-US PATENT RIGHTS upon the terms and
conditions hereinafter set forth. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties
hereto, intending to be legally bound, agree as follows: 
 ARTICLE 1 – DEFINITIONS 

For purposes of this Agreement, the following words and phrases shall have the following meanings: 

 

	1.1	“AFFILIATE” shall mean, with respect to the UNIVERSITY, any clinical or research entity that is operated or managed as a facility under the UPMC Health System, whether or not owned by UNIVERSITY.


  

	1.2	“COMMERCIALLY REASONABLE BEST EFFORTS” shall mean, with respect to the research, development and commercialization of any product, compound or process, [***]. 


 

	1.3	“LICENSEE” shall mean Exagen Diagnostics, Inc. and all entities at least fifty percent (50%) owned or controlled by Exagen Diagnostics, Inc. 


 

	1.4	“LICENSED TECHNOLOGY” shall mean any product or part thereof or service which is: 

  

	 	(a)	Covered in whole or in part by an issued, unexpired or pending claim contained in the PATENT RIGHTS in the country in which any such product or part thereof is made, used or sold or in which any such service is used or
sold; or 

  

	 	(b)	 Manufactured by using a process or is employed to practice a process which is covered in whole or in part by an issued, unexpired claim or a pending
claim contained in the PATENT RIGHTS in the country in which any such process that is included in the SLE FIELD or the MONITORING OF ORGAN 



  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 2 









	 	
TRANSPLANTATION & ORGAN REJECTION FIELD is used or in which such product or part thereof or service is used or sold. 


 

	1.5	“NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES” shall mean use of PATENT RIGHTS (including distribution of biological materials covered by the PATENT RIGHTS) for academic research or other not-for-profit
scholarly purposes which are undertaken at a nonprofit or governmental institution that does not use the PATENT RIGHTS in the production or manufacture of products for sale or the performance of services for a fee. 


 

	1.6	“NON-ROYALTY SUBLICENSE INCOME” shall mean [***] 

  

	1.7	“PATENT RIGHTS” shall mean UNIVERSITY intellectual property described below and assigned to the UNIVERSITY: 

  

	 	(a)	The foreign patents and/or patent applications listed in Exhibit A; 

  

	 	(b)	Foreign patents issued from the applications listed in Exhibit A and from divisionals and continuations and continuations in part of these applications; and 


 

	 	(c)	Claims of foreign continuation in part and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the foreign applications listed in Exhibit A.



  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 3 









	1.8	“NET SALES” shall mean gross [***] price actually charged by LICENSEE or its Sublicensee to third parties for LICENSED TECHNOLOGY and services or testing using the LICENSED TECHNOLOGY and services, less the
following deductions where they are factually applicable and are not already reflected in the gross invoice price: 

  

	 	(a)	Actual cost of freight, shipping and insurance charges or freight absorption, separately stated in such invoice; 

  

	 	(b)	Actual trade, quantity or cash discounts actually allowed, to include discounts to managed care organizations, so long as such discounts: (i) are in amounts customary in the trade, and (ii) do not violate
federal state laws or regulations; 

  

	 	(c)	Actual credits and allowances granted for product returns, rejection for damages and recalls; 

  

	 	(d)	Rebates paid or credited to managed care organizations and governmental agencies with respect to Medicaid, Medicare or similar state and federal government programs; and 


 

	 	(e)	Sales taxes, tariff duties and/or use taxes actually paid and separately stated on each invoice. 

  

	1.9	“SLE FIELD” shall mean any and all applications of the Patent Rights in Systemic Lupus Erythematosus. 

  

	1.10	“TERRITORY” shall mean worldwide, with the exception of the United States. 

  

	1.11	“MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD” shall mean any and all applications of the Patent Rights in Monitoring of Organ Transplantation & Organ Rejection.


 ARTICLE 2 – GRANT 
  

	2.1	 Subject to the terms and conditions of this Agreement, UNIVERSITY hereby grants to LICENSEE, to the extent it may lawfully do so, the right and
exclusive license in the 



  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 4 









	 	
TERRITORY to make, have made, use, offer for sale, import and sell the LICENSED TECHNOLOGY in the SLE FIELD and the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD and to
practice under the PATENT RIGHTS in the SLE FIELD and the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD to the end of the term for which the PATENT RIGHTS are granted, unless this Agreement is terminated as provided herein.
UNIVERSITY reserves the royalty-free, nonexclusive right to practice under the PATENT RIGHTS for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES and to use the LICENSED TECHNOLOGY for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES. 


 

	2.2	The license granted hereby is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. §200, et seq. Pursuant to this law, the United States government may have acquired a
nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the PATENT RIGHTS throughout the world. Pursuant to 35 U.S.C. §200, et seq. LICENSED TECHNOLOGY
produced for sale in the United States shall be substantially manufactured in the United States (unless a waiver under 35 U.S.C. §204 is granted by the appropriate United States government agencies). 


 

	2.3	LICENSEE shall have the right to enter into sublicensing arrangements (without the right to further sublicense) for the rights, privileges and licenses granted hereunder. Prior written approval of each sublicensee by
UNIVERSITY, which approval shall not be unreasonably withheld or delayed, will be required for all sublicensees except in such cases where the sublicensee: (1) has at least one FDA approved medical diagnostic test currently on the market: and
(2) has yearly revenues from the commercial sale of diagnostic products in excess of [***] dollars ($[***]). Upon termination of this Agreement, rights of any sublicensee granted by Licensee pursuant to this Section 2.3 shall survive such
termination at the written request of such sublicensees provided to UNIVERSITY, provided that the action or inaction of such sublicensee was not the cause of such termination. 


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 5 









	2.4	LICENSEE agrees that any sublicense granted by it shall provide that the obligations to UNIVERSITY of Articles 2, 7, 8, 9, 10, and 13 of this Agreement shall be binding upon the sublicensee as if it were party to this
Agreement. Each sublicense granted by LICENSEE pursuant to this Agreement shall include an audit right by UNIVERSITY of sublicensee of the same scope as provided in Section 5.2 with respect to LICENSEE. 


 

	2.5	LICENSEE agrees to forward to UNIVERSITY a copy of any and all sublicense agreements promptly upon execution thereof, but in no event later than thirty (30) days after each such sublicense agreement has been
executed by both parties thereto. 

  

	2.6	The license granted hereunder shall not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any technology other than PATENT RIGHTS. 


ARTICLE 3 – DUE DILIGENCE 
  

	3.1	LICENSEE shall use its [***] to bring the LICENSED TECHNOLOGY to market outside the United States as soon as practicable, consistent with sound and reasonable business practice and judgment, and to continue active,
diligent marketing efforts outside the United States for the LICENSED TECHNOLOGY throughout the term of this Agreement. 

  

	3.2	In addition, LICENSEE shall adhere to each of the following milestones: 

  

	 	(a)	Within thirty (30) months from the Effective Date of this Agreement, execute a commercial partnership agreement with a third party, or be acquired by a third party, for the purpose of commercialization of the
LICENSED TECHNOLOGY outside the United States; and 

  

	 	(b)	Within fifty-four (54) months from the Effective Date of a commercial partnership agreement with a third party, or an acquisition by a third party, achieve first commercial sale of LICENSED TECHNOLOGY outside of
the United States. 

  

	3.3	 LICENSEE’s failure to perform in accordance with Section 3.1 or to fulfill on a timely basis anyone of the milestones set forth in
Section 3.2 hereof shall be grounds for 



  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 6 









	 	
UNIVERSITY to terminate this Agreement pursuant to Section 10.2(a); except that for a single time, if a milestone in Section 3.2 has not been completed within the time frame allotted
through no fault of LICENSEE and following the best efforts of LICENSEE to meet such milestone, LICENSEE may, on a one-time basis, notify the UNIVERSITY in writing that it desires a single six (6) month extension to meet such milestone and
LICENSEE shall be deemed to have fulfilled the milestone requirement if LICENSEE makes a penalty payment of [***] dollars ($[***]) with both notice and penalty payment to be received by the UNIVERSITY within ten days of the applicable milestone
achievement date. In such case the LICENSEE and UNIVERSITY shall negotiate a new time for attainment of such missed milestone (not to exceed six months) and subsequent timeframes relying upon the meeting of previous milestones may also be adjusted.
If LICENSEE fails to meet any revised milestone including first missed milestone, UNIVERSITY may terminate the License and upon termination all rights and interest to the PATENT RIGHTS and any other rights granted by UNIVERSITY shall revert to
UNIVERSITY. 

  

	3.4	LICENSEE shall notify UNIVERSITY in writing of the achievement of each milestone in Section 3.2 within thirty (30) days upon the achievement of the respective milestone. 


ARTICLE 4 – LICENSE CONSIDERATION 
  

	4.1	In consideration of the rights, privileges and license granted by UNIVERSITY hereunder, LICENSEE shall pay royalties and other monetary consideration as follows: 


 

	 	(a)	Initial license fee, nonrefundable and noncreditable against royalties, of [***] Dollars ($[***]) due immediately and payable within ten (10) business days from the Effective Date of this Agreement;


  

	 	(b)	Royalties in an amount equal to [***] Percent ([***]%) of NET SALES of the LICENSED TECHNOLOGY per calendar quarter and royalties in an amount equal to [***] Percent ([***]%) of sublicensee NET SALES per calendar
quarter; 

  

	 	(c)	A share of NON-ROYALTY SUBLICENSE INCOME of [***] Percent ([***]%). 


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 7 









	4.2	In the event that it should prove necessary for LICENSEE to license intellectual property rights owned by a third party in order to practice the LICENSED TECHNOLOGY in the SLE FIELD or the MONITORING OF ORGAN
TRANSPLANTATION & ORGAN REJECTION FIELD in order to avoid infringing the patent or other intellectual property rights of such third party, then LICENSEE shall be entitled to a credit of such third party royalties against royalties due to
UNIVERSITY under Section 4.1(b) provided that (i) in no event shall the royalty rate applicable to NET SALES in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD be less than [***] percent ([***]%)
and (ii) in no event shall the royalty rate applicable to NET SALES in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD from a sub-Licensee be less than [***] percent ([***]%). 


 

	4.3	All payments pursuant to this Agreement may be made by check or by wire transfer (along with applicable wire transfer, transaction, and/or foreign translation fees) in United States dollars without deduction or
exchange, collection or other charges and directed to the address or, in the case of wire transfer, to the bank, set forth in Article 11. Royalty payments pursuant to Section 4.1(b) hereof shall be due within sixty (60) days after each
March 31, June 30, September 30 and December 31. NON-ROYALTY SUBLICENSE INCOME payments pursuant to Section 4.1(c) hereof shall be paid within thirty (30) days after receipt of payment by LICENSEE from
sublicense. Payments under Section 4.1(b) are payable on a country by country basis only in those countries in which there are PATENT RIGHTS with respect to the applicable LICENSED TECHNOLOGY. 


 

	4.4	Taxes imposed by any foreign or United States governmental agency on any payments to be made to UNIVERSITY by LICENSEE shall be paid by LICENSEE without deduction from any payment due to UNIVERSITY hereunder.


  

	4.5	 The balance of any payments pursuant to this Agreement, including those specified in Section 6.2, which are overdue shall bear interest,
compounded monthly, calculated from the due date until payment is received at the rate of five percent (5%) per annum, or the prime rate (as quoted by The Wall Street Journal) plus two percent (2%), whichever is




  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 8 









	 	
higher. Payment of such interest by LICENSEE shall not negate or waive the right of UNIVERSITY to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency
of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. Licensee shall reimburse University for any costs and expenses incurred in connection with collecting any overdue balance of payments with
respect to Licensee’s payment and reimbursement obligations under this Agreement, including the costs of engaging counsel or a collection agency for such purpose. 


 

	4.6	LICENSEE shall sell products and/or services resulting from LICENSED TECHNOLOGY to UNIVERSITY and its AFFILIATES upon request at such price(s) and on such terms and conditions as such products and/or services are made
available to LICENSEE’S most favored customer. 

 ARTICLE 5 – REPORTS AND AUDIT 

 

	5.1	Within sixty (60) days after each March 31, June 30, September 30 and December 31 of each year during the term of this Agreement beginning in the year of the first commercial sale of
LICENSED TECHNOLOGY, LICENSEE shall deliver to UNIVERSITY true, accurate and detailed reports of the following information in a form as illustrated in Exhibit B: 

  


	 	(a)	Number of product and service NET SALES for LICENSEE and all sublicensees; 

  

	 	(b)	Total billings and receivables for all such products and services; 

  

	 	(c)	Deductions set forth in Section 1.8, each stated separately; 

  

	 	(d)	Total royalties due; 

  

	 	(e)	Name and addresses of sublicensees; and 

  

	 	(f)	Total NON-ROYALTY SUBLICENSE INCOME received during such calendar quarter and total amount of payment due pursuant to Section 4.1(c). 


  
 9 









	5.2	LICENSEE shall keep full, true and accurate books of account, in accordance with generally accepted accounting principles, containing all information that may be necessary for the purpose of showing the amounts payable
to UNIVERSITY hereunder. Such books of account shall be kept at LICENSEE’S principal place of business. Such books of account shall be open at all reasonable times for [***] years following the end of the calendar year to which they pertain,
and for [***] years after the expiration or termination of this Agreement, for inspection by UNIVERSITY or its agents for the purpose of verifying LICENSEE’S royalty statement or compliance in other respects with this Agreement. The fees and
expenses of UNIVERSITY’S representatives shall be borne by UNIVERSITY; however, if an error of more than [***] percent ([***]%) of the total payments due or owing for any year is discovered, then LICENSEE shall bear UNIVERSITY’S fees and
expenses. 

  

	5.3	No later than ninety (90) days after December 31 of each calendar year during the term of this Agreement, LICENSEE shall provide to UNIVERSITY a written annual progress report, as illustrated in Exhibit C,
describing LICENSEE’S progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceding twelve-month period ending December 31. 


 

	5.4	Notwithstanding the above, UNIVERSITY shall have the right, on an annual basis during the term of this Agreement to inspect technical and other information from LICENSEE sufficient to evidence whether and to what extent
LICENSEE is: (a) practicing the PATENT RIGHTS; and (b) meeting its diligence obligations under Article 3, above. 

  

	5.5	LICENSEE shall report to the UNIVERSITY the date of the first commercial sale of a LICENSED TECHNOLOGY within sixty (60) days of occurrence in each country. 


ARTICLE 6 – PATENT PROSECUTION 
  

	6.1	 UNIVERSITY has or shall apply for and seek prompt issuance of and maintain during the term of this Agreement the PATENT RIGHTS in such foreign
countries as may be designated by LICENSEE in a written notice to UNIVERSITY within a reasonable time in advance of the required foreign filing dates. LICENSEE shall have the opportunity to




  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 10 









	 	
advise and cooperate with UNIVERSITY in the prosecution, filing and maintenance of such patents. If UNIVERSITY decides to abandon the preparation, filing, prosecution or maintenance of any patent
or patent application covered by the PATENT RIGHTS, then UNIVERSITY shall provide written notice to LICENSEE, and LICENSEE shall have the right at its sole expense to assume control of the preparation, filing, prosecution and maintenance of such
patent application or patent. If LICENSEE no longer wishes to support the prosecution or maintenance of any patent or patent application covered by the PATENT RIGHTS, then LICENSEE shall provide written notice to UNIVERSITY, and LICENSEE shall not
be responsible for such corresponding patent expenses that are incurred subsequent to the date of receipt by UNIVERSITY of such written notice by LICENSEE; such returned patent or patent application shall be excluded from the PATENT RIGHTS. Licensee
shall notify UNIVERSITY immediately if, at any time during the term of this Agreement, LICENSEE or any of its sublicensees does not qualify as a “Small Entity” as provided by the United States Patent and Trademark Office.


  

	6.2	All fees and costs, including attorneys’ fees, relating to the filing, prosecution, maintenance, and post grant proceedings relating to the PATENT RIGHTS shall be the responsibility of LICENSEE, whether incurred
prior to or after the Effective Date. LICENSEE shall not be required to reimburse the UNIVERSITY for any fees under this section that have been paid to the UNIVERSITY by prior licensees or any other third party. Fees and costs incurred shall be paid
by LICENSEE within thirty (30) days after receipt of UNIVERSITY’S invoice therefor. Additionally, Licensee shall be liable to UNIVERSITY for all of UNIVERSITY’S out-of-pocket filing, prosecution, and maintenance costs (including all
attorneys’ fees and costs), for any and all patent prosecution and maintenance actions that will be taken by patent counsel after the term of this Agreement but in response to any instructions that were sent during the term of this Agreement
from UNIVERSITY to patent counsel relating to the PATENT RIGHTS, with the proviso that such instructions were approved in writing by LICENSEE. Payments pursuant to this Section 6.2 are not creditable against royalties or any other payment due
to UNIVERSITY under this Agreement. 


  
 11 









	6.3	LICENSEE shall own any new patent application, and any patent that issues therefrom, or new technology in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD developed independently
of the UNIVERSITY and UNIVERSITY employees and shall not owe the UNIVERSITY any fee or royalty under section 4 relating to such a new patent application, and any patent that issues therefrom, or new technology. 


ARTICLE 7 – INFRINGEMENT ACTIONS 
  

	7.1	LICENSEE shall inform UNIVERSITY promptly in writing of any alleged infringement of the PATENT RIGHTS by a third party and of any available evidence thereof. 


 

	7.2	During the term of this Agreement, LICENSEE shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the PATENT RIGHTS in the SLE FIELD or the MONITORING OF ORGAN
TRANSPLANTATION & ORGAN REJECTION FIELD and in the TERRITORY if LICENSEE has notified UNIVERSITY in writing of its intent to prosecute; provided, however, that such right to bring such an infringement action shall remain in effect only for
so long as the license granted herein remains exclusive. In furtherance of such right, UNIVERSITY hereby agrees that LICENSEE may include UNIVERSITY as a party plaintiff in any such suit, without expense to UNIVERSITY. [***] 


 

	7.3	 If within six (6) months after having been notified of any alleged infringement, LICENSEE shall have been unsuccessful in persuading the alleged
infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, or if LICENSEE shall notify UNIVERSITY at any time prior thereto of its intention not to bring suit against any alleged infringer, then,
and in those events only, UNIVERSITY shall have the right, but shall not be obligated, to prosecute at its own expense any 



  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 12 









	 	
infringement of the PATENT RIGHTS, and UNIVERSITY may, for such purposes, use the name of LICENSEE as party plaintiff. [***] 


 

	7.4	In the event that a declaratory judgment action alleging invalidity or infringement of any of the PATENT RIGHTS shall be brought against UNIVERSITY, LICENSEE, at its option, shall have the right, within thirty
(30) days after commencement of such action, to intervene and take over the sole defense of the action at its own expense. 

  

	7.5	In any infringement suit either party may institute to enforce PATENT RIGHTS pursuant to this Agreement, the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects
and, to the extent possible, have its employees testify when requested and make available relevant records, information, samples, specimens, and other evidence upon request. 


ARTICLE 8 – INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY 

 

	8.1	 LICENSEE shall at all times during the term of this Agreement and thereafter indemnify, defend and hold UNIVERSITY, its trustees, officers, faculty
member, employees and Affiliates (“INDEMNIFIED PARTIES”) harmless against all claims and expenses, including legal expenses and reasonable attorneys’ fees, arising out of the death of or injury to any person or persons or out of any
damage to property or the environment, and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from: (i) the production, manufacture, sale, use, lease, consumption or advertisement of the LICENSED
TECHNOLOGY by Licensee to its sublicensees, (ii) the practice by LICENSEE or any Affiliate or sublicensee of the PATENT RIGHTS; or (iii) arising from or relating to this License Agreement. LICENSEE shall provide this defense and indemnity
whether or not any INDEMNIFIED PARTIES, either jointly or severally, is named as a party defendant and whether or not any INDEMNIFIED PARTIES is alleged to be negligent or otherwise responsible for any injuries to person or property. The obligation
of LICENSEE to defend and indemnify as set forth herein shall 



  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 13 









	 	
survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement. 


 

	8.2	LICENSEE shall obtain and carry in full force and effect liability insurance which shall protect LICENSEE and UNIVERSITY in regard to events covered by Section 8.1 above, as provided below: 


 

					
	 	  	 COVERAGE
	  	 LIMITS

			
	(a)	  	Commercial General Liability, including, but not limited to, Products, Contractual, Fire, Legal and Personal Injury	  	$1,000,000 Combined Single Limits for Bodily Injury and Property Damage
			
	(b)	  	Professional Liability	  	$5,000,000
			
	(c)	  	Products Liability	  	$5,000,000, to be effective on or before the date of first sale of LICENSED TECHNOLOGY products.

 The UNIVERSITY of Pittsburgh is to be named as an additional insured with respect to insurance policies
identified in Sections 8.2(a), 8.2(b), and 8.2(c) above. Certificates of insurance evidencing the coverage required above shall be filed with the UNIVERSITY’S Office of Technology Management, 200 Gardner Steel Conference Center,
Pittsburgh, PA 15260, no later than fifteen (15) days after execution of this Agreement and annually thereafter. Such certificates shall provide that the insurer will give the UNIVERSITY not less than thirty (30) days advance written
notice of any material changes in or cancellation of coverage. 
  

	8.3	 UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATION AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT
LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT THE PRACTICE BY LICENSEE OF THE
LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD 



  
 14 









	 	
PARTY. UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT,
SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE
MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT THAT IS MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE
SALES) WHICH IS LICENSED TECHNOLOGY HEREUNDER. 

 ARTICLE 9 – ASSIGNMENT 

Except as expressly provided hereunder, this Agreement is not assignable without the prior written consent of UNIVERSITY which consent shall
not be unreasonably withheld, and any attempt to do so shall be null and void, provided that LICENSEE may assign this Agreement and its rights and obligations thereunder, without the UNIVERSITY’S prior written consent in connection with the
transfer or sale of all or substantially all of the LICENSEE’S business relating to the PATENT RIGHTS and LICENSED TECHNOLOGY to a third party, whether by merger, sale of stock, sale of assets or otherwise subject to LICENSEE providing at least
10 business days written notification to UNIVERSITY and further subject to the assignee agreeing in writing to be bound to all the terms and conditions of this License. The rights and obligations of the parties under this Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Article 9 shall be null and void. 

ARTICLE 10 – TERM AND TERMINATION 
  

	10.1	This Agreement shall terminate upon the expiration of the last surviving claim of the PATENT RIGHTS. 


  
 15 









	10.2	UNIVERSITY shall have the right to terminate this Agreement, upon written notice, if: 

  

	 	(a)	LICENSEE defaults in the performance of any of the obligations herein contained and such default has not been cured within [***] days after receiving written notice thereof from UNIVERSITY; or 


 

	 	(b)	LICENSEE ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of
debtors. 

  

	10.3	LICENSEE may terminate this Agreement upon six (6) months prior written notice to UNIVERSITY and upon payment of all amounts accrued or due to UNIVERSITY through the effective date of termination, including patent
cost reimbursement pursuant to Article 6 hereof. 

  

	10.4	Upon termination of this Agreement, neither party shall be released from any obligation that matured prior to the effective date of such termination. LICENSEE and any sublicensee may, however, after the effective date
of such termination, sell all products under the LICENSED TECHNOLOGY which LICENSEE produced prior to the effective date of such termination, provided that LICENSEE shall pay to UNIVERSITY the royalties thereon as required by Article 4 hereof and
submit the reports required by Article 5 hereof. 

 ARTICLE 11 – NOTICES 

 

	11.1	Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed
to the address below or as either party shall designate by written notice to the other party, or if in accordance with Section 11.3. 

  

			
	In the case of University:
		
		 	Associate Vice Chancellor for Technology Management and Commercialization


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 16 









			
		 	Office of Technology Management
		 	University of Pittsburgh
		 	200 Gardner Steel Conference Center
		 	Thackeray & O’Hara Streets
		 	Pittsburgh, PA 15260
	
	In the case of LICENSEE:
		
		 	Exagen Diagnostics, Inc.
		 	800 Bradbury Drive SE
		 	Suite 108
		 	Albuquerque, NM 87106
		 	Attn: President and CEO

  

	11.2	Any payments to University hereunder by wire transfer shall be directed as follows: 

  

					
		 	Bank: Mellon Bank, NA, Pittsburgh, PA
		 	ABA Routing No.: 043000261-University of Pittsburgh
		 	Account No.: 0015510
		 	Mellon SWIFT Code: MELNUS3P (international transfers)
		 	Reference Code:	 	 Office of Technology Management, Accountant -

otmfinbx@pitt.edu - (412) 648-2226


 LICENSEE shall be responsible for all applicable fees and costs relating to any wire transfer, to include
translation fees, without any deduction of such fees from amounts due to the UNIVERSITY pursuant to this Agreement. 
  

	11.3	All invoices to LICENSEE generated by UNIVERSITY under this Agreement will be sent electronically, via e-mail, in PDF format, unless instructed otherwise by LICENSEE in writing. 


ARTICLE 12 – AMENDMENT, MODIFICATION 

This Agreement may not be amended or modified except by the execution of a written instrument signed by the UNIVERSITY’S Executive Vice
Chancellor, or its successor and/or designated UNIVERSITY employee having signatory authority, and LICENSEE’S President. In connection with any agreed upon amendment or modification of this Agreement pursuant to this Article 12, LICENSEE shall
be required to pay an Amendment Fee. 

  
 17 








 ARTICLE 13 – MISCELLANEOUS 

 

	13.1	This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania. The forum for any action relating to this Agreement, including those brought against individuals such as
UNIVERSITY employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the United States District Court for the Western District of Pennsylvania. 


 

	13.2	The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or
understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement. 

  

	13.3	Nothing contained in this Agreement shall be construed as conferring upon either party any right to use in advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of
the other party, including any contraction, abbreviation, or simulation of any of the foregoing. Without the express written approval of the other party, neither party shall use any designation of the other party in any promotional activity
associated with this Agreement or the LICENSED TECHNOLOGY. Neither party shall issue any press release or make any public statement in regard to this Agreement without the prior written approval of the other party, except LICENSEE may make such
disclosures as are necessary or appropriate to comply with its obligations under applicable laws, rules and regulations of the Securities and Exchange Commission and securities exchange upon which LICENSEE’S securities are listed.


  

	13.4	If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the remaining provisions shall not in any way be affected or impaired thereby. In the event any provision is held
illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as is practical, implements purposes of the provision held invalid, illegal or unenforceable. 


 

	13.5	 Failure at any time to require performance of any of the provisions herein shall not waive or diminish a party’s right thereafter to demand
compliance therewith or with any other 



  
 18 









	 	
provision. Waiver of any default shall not waive any other default. A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and signed by a duly
authorized officer of the party making such waiver. 

  

	13.6	LICENSEE acknowledges that UNIVERSITY is free to publish the results of the research activities of its faculty, staff and students, even though such publication may involve the PATENT RIGHTS or LICENSED TECHNOLOGY.
UNIVERSITY agrees to submit to LICENSEE any proposed publication or presentation regarding the subject matter specifically described in the PATENT RIGHTS for prior review by LICENSEE at least [***] days before its submittal for publication or its
presentation. LICENSEE may, within [***] days after receipt of such proposed publication, request that such proposed publication be delayed not more than [***] days in order to allow for protection of intellectual property rights. 


 

	13.7	 The term “Confidential Information” shall mean any and all proprietary or confidential information of UNIVERSITY or LICENSEE which may be
exchanged between parties at any time and from time to time during the term of this Agreement. Information shall not be considered confidential to the extent that either party can establish by competent proof that it: (i) is publically
disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; (ii) was known to the receiving party prior to the date of this Agreement, which knowledge was acquired independently and not from
another party hereto (or such party’s employees); (iii) is subsequently disclosed to the receiving party in good faith by a third party who has a right to make such disclosure; or (iv) has been published by a third party as a matter
of right. The parties agree that during the term of this Agreement, and for a period of [***] years after this Agreement terminates, a party receiving Confidential Information of the other party will (a) maintain in confidence such Confidential
Information; (b) not disclose such Confidential Information to any third party and (c) not use such confidential Information for any purpose except those permitted in this Agreement. Notwithstanding the foregoing, if a party is required by
law, regulation or court order to disclose Confidential Information of the other party, the party required to make such disclosure shall limit the same to the minimum required to make such disclosure shall limit the same to the minimum required




  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 19 









	 	
to comply with the law or court order, and shall use reasonable efforts to attempt to seek confidential treatment for that disclosure, and prior to making such disclosure that party shall notify
the other party shall notify the other party, not later than ten (10) days (or shorter period of time as may be practicable under the circumstances) before the disclosure in order to allow that other party to comment and/or to obtain protective
or other order, including extensions of time and the like, with respect to such disclosure. In addition, a party may disclose Confidential Information to the other party to employees, to sublicensees and potential sublicensees (in the case of
LICENSEE), or to other third parties in connection with due diligence or similar investigations by third parties or potential third party investors in confidential financing document, provided, in each case, that any such employee, consultant,
agent, sublicense, potential sublicense or other third party agrees in writing to be bound by terms of confidentiality and non-use at least as stringent as those set forth in this Section 13.7. 


 

	13.8	The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult, with their legal counsel and/or other advisors with respect to the PATENT RIGHTS, LICENSED TECHNOLOGY, and the terms of
this Agreement. 

  

	13.9	The parties agree that this Agreement constitutes an arm’s length business transaction and does not create a fiduciary relationship. 


 

	13.10	LICENSEE agrees that with respect to the performance of this Agreement or the practice of the rights granted by the UNIVERSITY hereunder, it shall comply with any and all applicable United States export control laws and
regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department’s Office of Foreign Asset Controls. 

  

	13.11	 If LICENSEE challenges the validity or enforceability of UNIVERSITY’S PATENT RIGHTS or UNIVERSITY’S ownership of the PATENT RIGHTS anywhere
in the world, the LICENSEE shall continue to pay to UNIVERSITY all royalties and other financial obligations required under this Agreement, to include patent costs and fees. If any such challenge is unsuccessful by Licensee, the royalty rates
and any non-royalty sublicense income rate set forth in Article 4.1 above shall automatically double in value, 



  
 20 









	 	
to include all royalty minimums and floors; and Licensee shall reimburse the University for all fees and costs associated with defending such action, including but not limited to attorneys fees
and expert fees. The effective date of such increase in royalty rates shall be the date of the first court order or date of issuance of a re-examination certificate (or foreign equivalents thereof) declaring any claim of the PATENT RIGHTS
as valid or enforceable. Within thirty (30) days prior to filing any such challenge, LICENSEE shall provide the UNIVERSITY with written notice of its intent to make such challenge. 


 

	13.12	Licensee shall mark all Licensed Technology with applicable foreign patent numbers in accordance with the applicable laws of the countries in which Licensed Technology is used or sold. 


[remainder of page intentionally left blank] 

  
 21 








 IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind the
party to this Agreement and have set their hands and seals as of the date set forth on the first page hereof. 
  

			
	UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
		
	By	 	 /s/ Jerome Cochran

		 	Jerome Cochran
		 	Executive Vice Chancellor
	
	EXAGEN DIAGNOSTICS, INC.
		
	By	 	 /s/ Ron Rocca

	Name:	 	Ron Rocca
	Title:	 	C.E.O.



  
 22 








 EXHIBIT A 

PATENT RIGHTS FOR EXCLUSIVE LICENSE AGREEMENT BETWEEN 

THE UNIVERSITY OF PITTSBURGH AND EXAGEN DIAGNOSTICS, INC. 
  

													
	 Univ.

Case

No.
	  	 Application No.
	  	 Application

Filing Date
	  	 Patent No.
	  	 Patent

Issuance

Date
	  	 Title
	  	 Country

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 










													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 24 









													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 25 









													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 26 









													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 27 









													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 28 









													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]


  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 


 
 29 








 EXHIBIT B 

SAMPLE ROYALTY REPORT 
 Licensee name: 

Reporting period: 
 Date of
report: 
 Royalty Reporting Form 
  

											
	 Product
	  	No. units sold
(including
sublicense)	  	Invoiced price
per unit	  	Gross sales	  	Allowable
deductions	  	Net sales
	 Product name
	  		  		  		  		  	
	 Product name
	  		  		  		  		  	
	 Product name
	  		  		  		  		  	
	 Product name
	  		  		  		  		  	
		  	  
	  	  
	  	  
	  	  
	  	  

	 Total
	  		  		  		  		  	
		  	  
	  	  
	  	  
	  	  
	  	  


  

					
	 Total net sales
	  	$	            	  
		  	  
	  
	 
	 Royalty rate
	  			
	 Royalty due
	  	$	            	  

 Total royalty due: $             

Name and addresses of sublicensees: 
 Total non-royalty sublicense
income: $             
 Report prepared by: 

Title: 
 Date: 

  
 30 








 EXHIBIT C 

SAMPLE PROGRESS REPORT 
 Licensee name:

 Report date: 
 Technology title: 

Progress Report 
  

	A.	Date development plan initiated and time period covered by this report 

  

	B.	Development report 

  

	 	1.	Activities, e.g., research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales, etc., completed since last report including the object and parameters of the development, when
initiated, when completed and the results 

  

	 	2.	Activities currently under investigations, i.e., ongoing activities including object and parameters of such activities, when initiated, and projected date of completion 


 

	C.	Future development activities 

  

	 	1.	Activities to be undertaken before next report including, but not limited to, the type and object of any studies conducted and their projected starting and completion dates 


 

	 	2.	Estimated total development time remaining before a product will be commercialized 

  

	D.	Changes to initial development plan 

  

	 	1.	Reasons for change 

  

	 	2.	Variables that may cause additional changes 

  

	E.	Items to be provided if applicable: 

  

	 	1.	Information relating to product that has become publicly available, e.g., published articles, competing products, patents, etc. 

  

	 	2.	Development work being performed by third parties other than Licensee to include name of third party, reasons for use of third party, planned future use of third parties including reasons why and type of work


  

	 	3.	Update of competitive information trends in industry, government compliance, and market plan 


  
 31